Drug Database
Back to search

France· FR:66677526

REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusion

A argipressin product containing acétate d'argipressine, registered in France by ORPHA DEVEL HANDELS & VERTRIEBS. The same ATC class is registered in 3 of our 19 countries.

ATC H01BA06

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedREVERPLEG 40 U.I./2 mL, solution à di…ATCH01BA06REGISTER NO.FR:66677526PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about acétate d'argipressineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Argipressin is registered in 3 of 19 countries.

Countries holding a registration under ATC H01BA06 (argipressin), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 1 of them publish a price we can compare per daily dose
Search argipressin products by name

Argipressin · ATC H01BA06

3 / 19 countries

  • Franceprice
  • Germany
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ACÉTATE D'ARGIPRESSINE
Manufacturer
ORPHA DEVEL HANDELS & VERTRIEBS
Country
France (FR)
ATC code
H01BA06
ATC class
Argipressin
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955055648
    10 ampoule(s) en verre de 2 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

166 interactions on record for argipressin.

Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check argipressin against other medicinesHow interaction checks work

Argipressin · interactions on record

166 records

  • 39 severe
  • 125 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Argipressin in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All argipressin products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Empesin
  • Belgium · Reverpleg
  • Bulgaria · Емпресин
  • Czechia · Embesin
  • Germany · Argipressin Farmak, Empressin
  • Denmark · Empressin
  • Estonia · Empesin
  • Spain · Empressin
  • Finland · Empressin
  • United Kingdom (Northern Ireland) · Argipressin Aop, Argipressin Mercury Pharmaceuticals
  • Greece · Empressin
  • Croatia · Empressin
  • Hungary · Embesyn
  • Ireland · Embesin
  • Italy · Empressin
  • Lithuania · Empesin
  • Luxembourg · Reverpleg
  • Latvia · Empesin
  • Netherlands · Empressine
  • Norway · Empressin
  • Poland · Argipressin Farmak, Empesin
  • Portugal · Empressin
  • Romania · Reverpleg
  • Sweden · Empressin
  • Slovenia · Empesin
  • Slovakia · Embesin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c2ef94d5-6632-4c82-8bce-6bdfa82100cf
GET /v1/drugs/c2ef94d5-6632-4c82-8bce-6bdfa82100cf?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66677526",
  "date_amm": "2018-05-31",
  "type_amm": "Procédure de reconnaissance mutuelle",
  "numero_ue": null,
  "substance": "ACÉTATE D'ARGIPRESSINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about argipressin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console